Sydney, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Australians planning for retirement income face two converging trends. Around 4.4 million Australians are now aged 65 and over, about 17% of the population, with Treasury's Intergenerational Report projecting that share to keep rising through 2063. At the same time, the country's 663,867 self-managed super funds hold A$1.06 trillion in assets across roughly 1.22 million members, according to the latest Australian Taxation Office data. Cash and term deposit allocations across the SMSF sector have fallen to 16.3% of holdings, a record low, as trustees look beyond traditional cash products towards the income side of the portfolio. To learn more visit https://termplus.com.au/how-it-works/
TORONTO, June 10, 2026 /CNW/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that shareholders of...
TORONTO, June 10, 2026 /PRNewswire/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that shareholders of...
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./TORONTO, June 10, 2026 /CNW/ - Canada...
WOODLAND PARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2026.
Toronto, ON, June 10, 2026 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (“Capstone” or the “Corporation”) (TSX:CSE.PR.A) announced today that it does not intend to exercise its right under the terms of its Cumulative 5-Year Rate Reset Preferred Shares, Series A (the “Series A shares”) to redeem all or part of the currently outstanding 3,000,000 Series A shares on July 31, 2026. As a result, subject to certain conditions, the holders of the Series A shares have the right to convert all or part of their Series A shares, on a one-for-one basis, into Cumulative Floating Rate Preferred Shares, Series B (the “Series B shares”) on July 31, 2026 (the “Conversion Date”) in accordance with the terms of the Series A shares.
Jiangsu, China, June 10, 2026 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (Nasdaq: MTEN) (the “Company”) today announced the closing of its previously announced registered direct offering of 1,131,004 Class A ordinary shares, par value $0.00005 per share (“Class A Ordinary Shares”), at a purchase price of $2.00 per share, and pre-funded warrants to purchase Class A Ordinary Shares at an original exercise price of $2.00, with $1.99995 of the original exercise price pre-funded at the closing, and a remaining exercise price of $0.00005 per Class A Ordinary Share.
AS PRFoods (registry code 11560713) hereby notifies that its subsidiary Saaremere Kala AS (registry code 11310040, hereinafter "Seller") has completed previously announced transaction (as disclosed in a stock exchange announcement published by AS PRFoods on 23 April 2026 (https://view.news.eu.nasdaq.com/view?id=1436682&lang=en), whereby 100% shareholding in Saare Kala Tootmine OÜ (registry code 10377013, hereinafter "SKT") was sold and claims arising from shareholder loans and an inventory loan provided to SKT were transferred to the Latvian company Brīvais Vilnis A/S (Latvian registry code: 40003056186, hereinafter "Buyer"). The general meeting of shareholders of AS PRFoods approved the transaction by their relevant resolution published on 18 May 2026 (https://view.news.eu.nasdaq.com/view?id=1442522&lang=en). In accordance with the terms of the transaction, the vendor note agreement concluded between the Seller and the Buyer and setting out the terms of the payment by the Buyer to the Seller of the amount equal to the outstanding purchase price for the share of SKT and of the transfer price for the inventory loans has entered into force upon completion of the transaction.
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026.